Emergent Biosolutions Inc (EBS) Short Interest Update

Emergent Biosolutions Inc (NYSE:EBS) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,455,334 shares, a drop of 40.8% from the November 30th total of 2,460,189 shares. Based on an average daily volume of 427,566 shares, the days-to-cover ratio is currently 3.4 days. Currently, 4.4% of the company’s shares are sold short.

A number of brokerages have commented on EBS. Wells Fargo & Co restated an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $53.00 price objective for the company in a research report on Tuesday, January 2nd.

Shares of Emergent Biosolutions (EBS) opened at $47.45 on Wednesday. Emergent Biosolutions has a 1 year low of $27.94 and a 1 year high of $49.25. The company has a market capitalization of $1,950.00, a PE ratio of 29.66, a price-to-earnings-growth ratio of 0.94 and a beta of 1.29. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million during the quarter, compared to analyst estimates of $124.55 million. During the same period last year, the company posted $0.56 EPS. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. equities analysts predict that Emergent Biosolutions will post 1.58 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 47,983 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the completion of the sale, the chairman now directly owns 1,550,216 shares in the company, valued at approximately $64,923,046.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Abdun-Nabi sold 21,906 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $47.91, for a total value of $1,049,516.46. Following the sale, the chief executive officer now owns 226,040 shares of the company’s stock, valued at $10,829,576.40. The disclosure for this sale can be found here. Insiders sold a total of 206,329 shares of company stock valued at $8,892,362 in the last quarter. 16.50% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Prudential Financial Inc. raised its stake in shares of Emergent Biosolutions by 3.6% during the 3rd quarter. Prudential Financial Inc. now owns 75,378 shares of the biopharmaceutical company’s stock worth $3,049,000 after purchasing an additional 2,618 shares in the last quarter. New Amsterdam Partners LLC NY raised its stake in shares of Emergent Biosolutions by 66.3% during the 3rd quarter. New Amsterdam Partners LLC NY now owns 163,337 shares of the biopharmaceutical company’s stock worth $6,607,000 after purchasing an additional 65,109 shares in the last quarter. Systematic Financial Management LP purchased a new stake in shares of Emergent Biosolutions during the 3rd quarter worth about $1,680,000. Macquarie Group Ltd. raised its stake in shares of Emergent Biosolutions by 60.1% during the 3rd quarter. Macquarie Group Ltd. now owns 41,573 shares of the biopharmaceutical company’s stock worth $1,681,000 after purchasing an additional 15,604 shares in the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Emergent Biosolutions by 169.2% during the 2nd quarter. First Trust Advisors LP now owns 53,149 shares of the biopharmaceutical company’s stock worth $1,802,000 after purchasing an additional 33,403 shares in the last quarter. 88.44% of the stock is owned by institutional investors.

WARNING: “Emergent Biosolutions Inc (EBS) Short Interest Update” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2018/01/10/emergent-biosolutions-inc-ebs-short-interest-update.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit